000835112 001__ 835112
000835112 005__ 20210129230823.0
000835112 0247_ $$2doi$$a10.1136/jnnp-2017-315878
000835112 0247_ $$2ISSN$$a0022-3050
000835112 0247_ $$2ISSN$$a0266-8637
000835112 0247_ $$2ISSN$$a0368-329X
000835112 0247_ $$2ISSN$$a1468-330X
000835112 0247_ $$2WOS$$aWOS:000407777300010
000835112 0247_ $$2Handle$$a2128/22022
000835112 0247_ $$2altmetric$$aaltmetric:20592135
000835112 0247_ $$2pmid$$apmid:28550073
000835112 037__ $$aFZJ-2017-04980
000835112 041__ $$aEnglish
000835112 082__ $$a610
000835112 1001_ $$0P:(DE-Juel1)158077$$aSchneider, Christian$$b0
000835112 245__ $$aLymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy
000835112 260__ $$aLondon$$bBMJ Publishing Group$$c2017
000835112 3367_ $$2DRIVER$$aarticle
000835112 3367_ $$2DataCite$$aOutput Types/Journal article
000835112 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554290567_32104
000835112 3367_ $$2BibTeX$$aARTICLE
000835112 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000835112 3367_ $$00$$2EndNote$$aJournal Article
000835112 520__ $$aObjective To identify the most relevant antigens for monoclonal antibodies in lymphocytic infiltrates in non-systemic vasculitic neuropathy (NSVN).Background Current immunosuppressive treatment for NSVN is insufficient. Monoclonal antibodies might be a treatment option, but the expression profile for targetable antigens on lymphocytic infiltrates in NSVN is unknown.Methods Sural nerve biopsies from a cohort of patients with NSVN were immunohistochemically studied for the expression of potential candidate antigens in perivascular and intramural lymphocytic infiltrates and correlated with neurological and electrophysiological parameters. 20 patients with treatment naïve NSVN and 5 patients with idiopathic axonal neuropathy were included.Results The CD52, BAFF and CD49d antigens were expressed in epineurial, perivascular or intramural lymphocytes of all (20/20) patients. CD52 was most prominently expressed in 21.49% of all inflammatory infiltrates. BAFF and CD49d were detected in 11.25% and 10.99% of these lymphocytes, respectively. The CD20, CD25 and CD126 antigens were found less frequently and at low levels only (CD20: 10/20 patients, 5.84% of lymphocytes; CD25: 17/20 patients, 5.22% of lymphocytes; CD126: 3/20 patients, 0.15% of lymphocytes).Conclusion This is the first study in NSVN that identifies antigens expressed by pathogenic lymphocytes, which are potential targets for future monoclonal antibody treatment. Our data suggest that NSVN is amenable to monoclonal antibodies and, moreover, that targeting CD52 may be particularly promising. Our results strongly warrant future clinical trials in NSVN with monoclonal antibodies.
000835112 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000835112 588__ $$aDataset connected to CrossRef
000835112 7001_ $$0P:(DE-HGF)0$$aWunderlich, Gilbert$$b1
000835112 7001_ $$0P:(DE-HGF)0$$aBleistein, Johannes$$b2
000835112 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b3
000835112 7001_ $$0P:(DE-HGF)0$$aDeckert, Martina$$b4
000835112 7001_ $$0P:(DE-HGF)0$$aBrunn, Anna$$b5
000835112 7001_ $$0P:(DE-HGF)0$$aLehmann, Helmar Christoph$$b6$$eCorresponding author
000835112 773__ $$0PERI:(DE-600)1480429-3$$a10.1136/jnnp-2017-315878$$gp. jnnp-2017-315878 -$$n9$$p756–760$$tJournal of neurology, neurosurgery, and psychiatry$$v88$$x1468-330X$$y2017
000835112 8564_ $$uhttps://juser.fz-juelich.de/record/835112/files/756.full.pdf$$yPublished on 2017-05-27. Available in OpenAccess from 2018-11-27.
000835112 8564_ $$uhttps://juser.fz-juelich.de/record/835112/files/756.full.pdf?subformat=pdfa$$xpdfa$$yPublished on 2017-05-27. Available in OpenAccess from 2018-11-27.
000835112 909CO $$ooai:juser.fz-juelich.de:835112$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000835112 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
000835112 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000835112 9141_ $$y2017
000835112 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000835112 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000835112 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000835112 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000835112 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL NEUROSUR PS : 2015
000835112 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000835112 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000835112 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000835112 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000835112 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000835112 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL NEUROSUR PS : 2015
000835112 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000835112 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000835112 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000835112 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000835112 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000835112 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000835112 920__ $$lyes
000835112 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000835112 980__ $$ajournal
000835112 980__ $$aVDB
000835112 980__ $$aUNRESTRICTED
000835112 980__ $$aI:(DE-Juel1)INM-3-20090406
000835112 9801_ $$aFullTexts